At Alvinesa, we continue to invest in science to demonstrate the real health benefits of our natural ingredients. We are proud to announce the publication of a new clinical study on Hytolive®, our natural olive extract standardized in hydroxytyrosol, in the prestigious journal Clinical Nutrition.
This randomized, double-blind, placebo-controlled clinical trial, conducted in collaboration with the CSIC (ICTAN) and the University of the Basque Country, involved 49 adults with overweight and prediabetes who consumed 15 mg of hydroxytyrosol daily for 16 weeks.
The results were statistically significant in seven key biomarkers, confirming the strong antioxidant and anti-inflammatory effects of Hytolive®. Compared with the placebo group, participants who took Hytolive® showed:
-
Reduced oxidized LDL (oxLDL), a key marker linked to cardiovascular risk.
-
Lower oxidative damage in proteins (protein carbonyls).
-
Reduced DNA oxidative damage (8-OHdG).
-
Maintenance of total antioxidant status (TAS).
-
Preservation of glutathione peroxidase (GPx) activity, a crucial antioxidant enzyme.
-
Reduced inflammation, with a significant decrease in interleukin-6 (IL-6).
-
Improved overall redox balance, protecting cells against oxidative stress and aging.
The study also assessed GLP-1, a hormone related to insulin function and glucose metabolism. Interestingly, while the placebo group showed a compensatory increase in GLP-1 —a typical response to metabolic stress—, this rise did not occur in the Hytolive® group, suggesting better metabolic stability and improved insulin sensitivity.
In simple terms, these results confirm that Hytolive® helps the body defend itself against oxidative damage and inflammation, supporting healthier metabolic function in people at risk of diabetes or cardiovascular disease.
📄 Reference:
